Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Crowdsourcing is a social phenomenon that is providing a platform for everything from funding small businesses to compiling data for research and development of pharmaceuticals and medical devices. Imagine the possibilities of being able to solve and predict disease challenges through the collective amalgamation of data without boundaries.
Companies such as AstraZeneca, Lilly, GSK, Janssen, Merck, Pfizer, Sanofi, TransCelerate, and others started launching crowdsourcing and open platform initiatives several years ago to enable scientific innovation to cross boundaries between companies, academia, government, and nonprofit organizations. This month’s Forum addresses how Additionally, these and other companies are expanding their approach beyond their internal development teams to issue challenges or competitions for folks to apply for grants for new research projects.
For example, in August, The Myeloma Crowd Research Initiative (MCRI), a collaboration of cancer researchers and patient advocates, announced the two winners of its first crowdsourcing and patient-led initiative to fund research in high-risk multiple myeloma, a rare malignancy of plasma cells. MCRI pledged up to $500,000 over two years for both grants combined.
This crowdsourcing approach, the focus of this month’s cover story, transcends proprietary and historically closed-door approaches to R&D and might just be the answer the industry needs to move the needle forward on diseases that have been difficult, if not impossible, to crack such as Alzheimer’s, Parkinson’s, and HIV.
For example, companies like Foldit are using the crowd to look at how different proteins fold. To date, Foldit has more than half a million registered players. The company is using algorithms to predict the structure of a protein through puzzle-solving scenarios, which would aid the creation of designing new proteins to combat disease-related proteins found in HIV/AIDS, cancer, or Alzheimer’s.
The Center for Game Science, which developed Foldit, is gearing to launch FolditTV to share protein-folding knowledge the community has gained over the years with a much larger audience.
2013 PharmaVOICE 100 honoree Jamie Haywood’s innovative social network approach to crowdsourcing — PatientsLikeMe — is making huge strides in connecting patients to share healthcare and treatment information.
Physicans’ networks such as Sermo are bringing together physicians in virtual online meeting places that facilitate discussions, online learning, and medical information sharing.
Other companies such as Helix, which is featured in this month’s Innovator’s Corner, is developing an online open platform that aims to unleash the creativity in the world of developers, providing an infrastructure for companies and software developers who want to reach consumers through mobile or Web-based applications. The goal is to empower consumers to discover insights into their own genome through an ecosystem of content partners.
Welcome to the crowd.
Open innovation and crowdsourcing is increasing as a way to gain access to new ideas and to spur innovation.
As more payers adopt a pay-for-performance formulary, oncology marketers need to address the treatment’s
value-add to the patient journey more than ever.
Opportunities and challenges abound in the Nigerian healthcare landccape.
Year in Preview
The 21st Century Cure
Analytic-Driven Approaches to Marketing
Smart Medical Technology
New Health Economy
Showcase Feature: E-Solutions
The forum for the industry executive
Volume 15 • Number 9
Publisher Lisa Banket
Editor Taren Grom
Creative Director Marah Walsh
Director of Sales
National Account Manager
Webcast Network Producer
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Fifteen, Number Nine
PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O. Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.
Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.
PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.
Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: email@example.com.
Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: firstname.lastname@example.org.
Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.
Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O. Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: email@example.com.